{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:30:01Z","timestamp":1774362601530,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Recep Tayyip Erdogan University Development Foundation","award":["02026002013124"],"award-info":[{"award-number":["02026002013124"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: We aimed to compare the treatment success and patient compliance of triple therapy with levofloxacin, high-dose dual therapy with amoxicillin, and quadruple therapy with bismuth and levofloxacin as first-line treatment for Helicobacter pylori (H. pylori) eradication using amoxicillin 875 mg + clavulanic acid 125 mg instead of amoxicillin 1 g. Methods: Patients who tested positive for Helicobacter pylori in the histopathological examination of biopsies taken during upper gastrointestinal endoscopy were initially divided into three different treatment groups. There were 179 patients in the first group, 178 patients in the second group, and 182 patients in the third group. A total of 480 patients from these groups who came for follow-up were included in this study, with 160 patients in each group receiving one of three different treatment protocols. The first group received treatment with amoxicillin 875 mg + 125 mg clavulanic acid twice daily, levofloxacin 500 mg once daily, and pantoprazole 40 mg twice daily (Group 1). The second group received treatment with amoxicillin 875 mg + 125 mg clavulanic acid three times a day, along with pantoprazole 40 mg twice daily (Group 2) as treatment. The third group received treatment with amoxicillin 875 mg + 125 mg clavulanic acid, twice daily, levofloxacin 500 mg once daily, pantoprazole 40 mg twice daily, and bismuth subsalicylate 262 mg2 pieces four times a day (Group 3). H. pylori was checked with a stool antigen test 45 days after the 14-day treatment. The groups were compared in terms of treatment success and treatment compliance. Results: In Group 1, 150 (90.6%) of 160 patients tested negative for an H. pylori antigen in stool samples on day 45 after treatment. This rate was 139 (86.9%) in Group 2 and 148 (92.5%) in Group 3. There were no statistically significant differences between the three groups in terms of treatment success (p = 0.233). Side effects were observed in 10 (6.2%) patients in Group 1. Side effects were present in nine (5.6%) patients in Group 2. Side effects were observed in 12 (7.5%) patients in Group 3. There was no significant difference between the groups in terms of patient compliance (p = 0.786). Conclusions: Treatment success and side effects were similar in all three groups, with no statistical difference. The combination of amoxicillin 875 mg + clavulanic acid 125 mg is at least as effective as amoxicillin 1 g alone.<\/jats:p>","DOI":"10.3390\/jcm15072480","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:58:59Z","timestamp":1774357139000},"page":"2480","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Comparison of the Efficacy and Tolerability of Quinolone-Based Triple Therapy, Quadruple Therapy, and High-Dose Amoxicillin Therapy in Helicobacter pylori Eradication"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5587-3667","authenticated-orcid":false,"given":"Halil","family":"Atasoy","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Recep Tayyip Erdogan University, Rize 53020, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akif","family":"Seyrekli","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Recep Tayyip Erdogan University, Rize 53020, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre","family":"Selim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Recep Tayyip Erdogan University, Rize 53020, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5396-5402","authenticated-orcid":false,"given":"Aziz","family":"Gumu\u015f","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, Recep Tayyip Erdogan University, Rize 53020, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caglayan","family":"Keklikkiran","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Recep Tayyip Erdogan University, Rize 53020, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-3781","authenticated-orcid":false,"given":"Recep","family":"Bedir","sequence":"additional","affiliation":[{"name":"Department of Pathology, Recep Tayyip Erdogan University, Rize 53020, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remzi Adnan","family":"Akdogan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Recep Tayyip Erdogan University, Rize 53020, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: The Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis","volume":"8","author":"Georges","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e12636","DOI":"10.1111\/hel.12636","article-title":"Review: Helicobacter pylori and extragastric diseases","volume":"24","author":"Franceschi","year":"2019","journal-title":"Helicobacter"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1001\/jama.282.23.2240","article-title":"Fecal and oral shedding of Helicobacter pylori from healthy infected adults","volume":"282","author":"Parsonnet","year":"1999","journal-title":"JAMA"},{"key":"ref_5","first-page":"288","article-title":"Prevalence and Sociodemographic Distribution of Helicobacter pylori Positivity in T\u00fcrkiye: A Retrospective Analysis between 2018\u20132023 and Impact of COVID-19 Measures","volume":"15","author":"Aygar","year":"2025","journal-title":"Value Health Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ozaydin, N., A Turkyilmaz, S., and Cali, S. (2013). Prevalence and risk factors of helicobacter pylori in Turkey: A nationally-representative, cross-sectional, screening with the 13C-Urea breath test. BMC Public Health, 13.","DOI":"10.1186\/1471-2458-13-1215"},{"key":"ref_7","first-page":"33","article-title":"The Prevalence of Helicobacter pylori Infection in Different Countries","volume":"2","author":"Pounder","year":"1995","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis","volume":"153","author":"Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: A systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/apt.14319","article-title":"Systematic review with meta-analysis: The global recurrence rate of Helicobacter pylori","volume":"46","author":"Hu","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"706507","DOI":"10.1155\/2015\/706507","article-title":"Is There Any Advantage of Treating Partners in Helicobacter pylori Eradication?","volume":"2015","author":"Rakici","year":"2015","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bpg.2006.11.002","article-title":"Diagnosis of Helicobacter pylori: Invasive and non-invasive tests","volume":"21","author":"Ricci","year":"2007","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.14309\/ajg.0000000000001828","article-title":"Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis","volume":"117","author":"Ho","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/j.1572-0241.2006.00668.x","article-title":"Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: A systematic review and meta-analysis","volume":"101","author":"Gisbert","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-Analysis in World Health Organization Regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5152\/tjg.2020.18631","article-title":"Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the Eastern Black Sea region of Turkey","volume":"31","author":"Erkut","year":"2020","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.14309\/ajg.0000000000001246","article-title":"Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)","volume":"116","author":"Nyssen","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000369788","article-title":"Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy","volume":"90","author":"Rakici","year":"2014","journal-title":"Digestion"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/apt.13712","article-title":"Systematic review with meta-analysis: The efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection","volume":"44","author":"Chen","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG Clinical Guideline: Treatment of Helicobacter pylori Infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.gastro.2021.10.048","article-title":"How We Approach Difficult to Eradicate Helicobacter pylori","volume":"162","author":"Argueta","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/j.gastro.2020.11.059","article-title":"AGA clinical practice update on the management of refractory Helicobacter pylori infection: Expert review","volume":"160","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Cho, J.-H., and Jin, S.-Y. (2024). Comparison of Amoxicillin Administered Twice versus Four Times a Day in First-Line Helicobacter pylori Eradication Using Tegoprazan, Clarithromycin, and Bismuth: A Propensity Score Matching Analysis. Microorganisms, 12.","DOI":"10.3390\/microorganisms12101952"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1053\/j.gastro.2024.06.038","article-title":"AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review","volume":"167","author":"Patel","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nyssen, O.P., Espada, M., and Gisbert, J.P. (2022). Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.913436"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Losurdo, G., Mezzapesa, M., Ditonno, I., Piazzolla, M., Pricci, M., Girardi, B., Celiberto, F., Galeano, G., Riezzo, G., and Russo, F. (2024). Helicobacter pylori Secondary Antibiotic Resistance after One or More Eradication Failure: A Genotypic Stool Analysis Study. Antibiotics, 13.","DOI":"10.3390\/antibiotics13040336"},{"key":"ref_28","first-page":"158520","article-title":"Levofloxacin-amoxicillin\/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection","volume":"2014","author":"Chen","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.0954-6820.2003.01239.x","article-title":"Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate","volume":"255","author":"Ojetti","year":"2003","journal-title":"J. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.dld.2005.07.010","article-title":"\u03b2-Lactamase inhibition with clavulanic acid supplementing standard amoxycillin-based triple therapy does not increase Helicobacter pylori eradication rate","volume":"37","author":"Crispino","year":"2005","journal-title":"Dig. Liver Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2480\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:46:19Z","timestamp":1774359979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15072480"],"URL":"https:\/\/doi.org\/10.3390\/jcm15072480","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}